MorphoSys To Host Conference Call To Provide Update On MOR103 Program

Martinsried / München, Germany, Jan 14, 2008 - (Hugin via ABN Newswire) - MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment) recently announced that it has submitted a clinical trial application (CTA) to initiate a phase 1 trial using the HuCAL-derived antibody MOR103 for the treatment of Rheumatoid Arthritis.

In order to provide detailed information on this announcement the Management Board of MorphoSys AG will host a public conference call and live audio webcast on Wednesday, January 16, 2008 at 10:00 CET.

Dial-in number: +49 (0)69 9897 2623 (listen-only) UK residents: +44 (0)20 7138 0843 Confirmation code: 5075940

The call will be hosted by:

Dr. Simon Moroney, Chief Executive Officer Dave Lemus, Chief Financial Officer Dr. Marlies Sproll, Chief Scientific Officer

MorphoSys AG offers participants the opportunity to follow the presentation through a simultaneous slide presentation online at http://www.morphosys.com

The presentation slides will be available on the Company's website.

A slide-synchronized audio replay of the conference will be available following the live event on http://www.morphosys.com/conferencecalls.

For further information please contact: Dr. Claudia Gutjahr-Löser, Head of Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-122, gutjahr-loeser@morphosys.com or Mario Brkulj, Manager Corporate Communications & Investor Relations, Tel: +49 (0) 89 / 899 27-454, brkulj@morphosys.com

Copyright © Hugin ASA 2008. All rights reserved.

MorphoSys AG

http://www.morphosys.com

ISIN: DE0006632003

Stock Identifier: XFRA.MOR

US: PINKSHEETS:MPHSF